腫瘍免疫学

出版社: 癌と化学療法社
著者:
発行日: 2010-09-24
分野: 臨床医学:一般  >  癌/腫瘍一般
ISBN: 9784906225446
電子書籍版: 2010-09-24 (初版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

5,500 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,750 円(税込)

商品紹介

急速に膨張しつつある腫瘍免疫の今日的な知識と理解を学ぶための格好の教科書である。膨大な研究結果を端的に伝え、解釈をくわえることにより、読む者を癌に対する免疫応答の仕組みの理解へと導いてくれる。

目次

  • 腫瘍免疫学

    ―目次―

    A. 総論 Cancer immunoediting
    B. 腫瘍細胞の微小環境下での免疫逃避
    C. 手術と免疫
    D. 免疫療法
    E. Immunogenic chemotherapy
    F. 腫瘍免疫関連事項
    G. 免疫抑制T細胞
    H. まとめ

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

A. 総論 Cancer immunoediting

P.5 掲載の参考文献

B. 腫瘍細胞の微小環境下での免疫逃避

P.8 掲載の参考文献
22) Liakou CI, Narayanan S, Ng Tang D, et al: Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun 7: 10, 2007.
P.15 掲載の参考文献
7) Chang CC, Ogino T, Mullins DW, et al: Defective human leukocyte antigen class I-associated antigen presentation caused by a novel β2-microglobulin loss-of-function in melanoma cells. J Biol Chem 281: 18763-18773, 2006.
16) Durda PJ, Dunn IS, Rose LB, et al: Induction of "antigen silencing" in melanomas by oncostatin M: downmodulation of melanocyte antigen expression. Mol Cancer Res 1: 411-419, 2003.
26) Pulaski BA, Ostrand-Rosenberg S: Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7. 1 cell-based tumor vaccines. Cancer Res 58: 1486-1493, 1998.
27) Concha A, Esteban F, Cabrera T, et al: Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol 2: 47-54, 1991.
29) Gutierrez J, Lopez-Nevot MA, Cabrera T, et al: Class I and II HLA antigen distribution in normal mucosa, adenoma, and colon carcinoma: Relation with malignancy and invasiveness. Exp Clin Immunogenet 4: 144-152, 1987.
31) Lopez-Nevot MA, Garcia E, Romero C, et al: Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas. Exp Clin Immunogenet 5: 203-212, 1988.
36) Muhlethaler-Mottet A, Di Berardino W, Otten LA, et al: Activation of the MHC class II transactivator C II TA by interferon-γ requires cooperative interaction between Stat1 and USF-1. Immunity 8: 157-166, 1998.
37) Sato A, Toyota M, Ikeda H, et al: Epigenetic inactivation of class II transactivator (C II TA) is associated with the absence of interferon-γ-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene 23: 8876-8886, 2004.
51) Zidi I, Guillard C, Marcou C, et al: Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-κB inducers. Cell Mol Life Sci 63: 2669-2681, 2006.
P.22 掲載の参考文献
12) Wrobel P, Shojaei H, Schittek B, et al: Lysis of a broad range of epithelial tumour cells by human γδ T cells: involvement of NKG2D ligands and T-cell receptor-versus NKG2D-dependent recognition. Scand J Immunol 66: 320-328, 2007.
17) Marten A, von Lilienfeld-Toal M, Buhler MW, et al: Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity. Intl Cancer 119: 2359-2365, 2006.
27) Marchetti A, Tinari N, Buttitta F, et al: Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res 62: 2535-2539, 2002.
31) Chung CD, Patel VP, Moran M, et al: Galectin-1 induces partial TCRζ-chain phosphorylation and antagonizes processive TCR signal transduction. J Immunol 165: 3722-3729, 2000.
38) Okada K, Komuta K, Hashimoto S, et al: Frequency of apoptosis of tumor-infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 6: 3560-3564, 2000.
43) Abrahams VM, Straszewski SL, Kamsteeg M, et al: Epithelial ovarian cancer secrete functionl Fas ligand. Cancer Res 63: 5573-5581, 2003.
45) Miwa K, Asano M, Horai R, et al: Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 4: 1287-1292, 1998.
P.26 掲載の参考文献
13) Strome SE, Dong H, Tamura H, et al: B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 63: 6501-6505, 2003.
P.34 掲載の参考文献
13) Sun J, Schiffman J, Raghunath A, et al: Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun 8: 9, 2008.
17) Levy L, Hill CS: Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 17: 41-58, 2006.
18) Wrzesinski SH, Wan YY, Flavell RA: Transforming growth factor-β and the immune response: implications for anticancer therapy. Clin Cancer Res 13: 5262-5270, 2007.
19) Teicher BA: Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev 20: 133-143, 2001.
20) Dong M, Blobe GC: Role of transforming growth factor-β in hematologic malignancies. Blood 107: 4589-4596, 2006.
22) Teicher BA: Transforming growth factor-β and the immune response to malignant disease. Clin Cancer Res 13: 6247-6251, 2007.
23) Song B-C, Chung Y-H, Kim JA, et al: Transforming growth factor-β1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 94: 175-180, 2002.
24) Xu WQ, Jiang XC, Zheng L, et al: Expression of TGF-β1, TβR II and Smad4 in colorectal carcinoma. Exp Mol Pathol 82: 284-291, 2007.
25) Arteaga CL: Inhibition of TGFβ signaling in cancer therapy. Curr Opin Genet Dev 16: 30-37, 2006.
26) Galliher AJ, Schiemann WP: β3 integrin and Src facilitate transforming growth factor-β mediated inductionof epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 8:R42, 2006.
27) McKarns SC, Schwartz RH, Kaminski NE: Smad3 is essential for TGF-β1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation. J Immunol 172: 4275-4284, 2004.
29) Shull MM, Ormsby I, Kier AB, et al: Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359: 693-699, 1992.
30) Kulkarni AB, Huh CG, Becker D, et al: Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90: 770-774, 1993.
31) Gorelik L, Flavell RA: Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12: 171-181, 2000.
32) Lucas P, Kim J-S, Melby SJ, et al: Disruption of T cell homeostasis in mice expressing a T cell-specificdominant negative transforming growth factor β II receptor. J Exp Med 191: 1187-1196, 2000.
33) Classen S, Zander T, Eggle D, et al: Human resting CD4+ T cells are constitutively inhibited by TGFβ under steady-state conditions. J Immunol 178: 6931-6940, 2007.
34) Eisele G, Wischhusen J, Mittelbronn M, et al: TGF-β and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 129: 2416-2425, 2006.
35) Castriconi R, Cantoni C, Della Chiesa M, et al: Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 100: 4120-4125, 2003.
36) Lee JC, Lee KM, Kim DW, et al: Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 172: 7335-7340, 2004.
37) Geissmann F, Revy P, Regnault A, et al: TGF-β1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 162: 4567-4575, 1999.
38) Liu VC, Wong LY, Jang T, et al: Tumor evasion of the immune system by converting CD4+CD25+ T cells into CD4+CD25- T regulatory cells: role of tumor-derived TGF-β. J Immunol 178: 2883-2892, 2007.
39) Pyzik M, Piccirillo CA: TGF-β1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets. J Leukoc Biol 82: 335-346, 2007.
40) Nam JS, Terabe M, Kang MJ, et al: Transforming growth factor β subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 68: 3915-3923, 2008.
41) Nam JS, Terabe M, Mamura M, et al: An anti-transforming growth factor β antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 68: 3835-3843, 2008.
42) Morris JC, Shapiro GI, Tan AR, et al: Phase I/II study of GC1008: A human anti-transforming growth factor-beta (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). 2008 ASCO Annual Meeting Proccedings: 489s.
43) Uhl M, Aulwurm S, Wischhusen J, et al: SD-208, a novel transforming growth factor β receptor I kinaseinhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64: 7954-7961, 2004.
44) Ge R, Rajeev V, Ray P, et al: Inhibition of growth and metastasis of mouse mammary carcinoma by selective nhibitor of transforming growth factor-β type I receptor kinase in vivo. Clin Cancer Res 12: 4315-3430, 2006.
45) Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, et al: SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 3: 737-745, 2004.
46) Suzuki E, Kim S, Cheung HK, et al: A novel small-molecule inhibitor of transforming growth factor β type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 67: 2351-2359, 2007.
48) Fakhrai H, Mantil JC, Liu L, et al: Phase I clinical trial of a TGF-β antisense-modified tumor cell vaccine inpatients with advanced glioma. Cancer Gene Ther 13: 1052-1060, 2006.
49) Moore LD, Isayeva T, Siegal GP, et al: Silencing of transforming growth factor-β1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo. Clin Cancer Res 14: 4961-4970, 2008.
51) Masferrer JL, Leahy KM, Koki AT, et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306-1311, 2000.
54) Jung YJ, Isaacs JS, Lee S, et al: IL-1β-mediated up-regulation of HIF-1α via an NFκB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 17: 2115-2117, 2003.
69) Lonnroth C, Andersson M, Arvidsson A, et al: Preoperative treatment with a non-steroidal antiinflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun 8: 5, 2008.
76) Oyama T, Ran S, Ishida T, et al: Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells. J Immunol 160: 1224-1232, 1998.
79) Belotti D, Paganoni P, Manenti L, et al: Matrix metalloproteinase (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 63: 5224-5229, 2003.
88) Krockenberger M, Dombrowski Y, Weilder C, et al: Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol 180: 7338-7348, 2008.
P.42 掲載の参考文献
4) Yano H, lshida T, Inagaki A, et al: Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer 120: 2052-2057, 2007.
5) Yang ZZ, Novak AJ, Ziesmer SC, et al: CD70+ non-Hodgikin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25- T cells. Blood 110: 2537-2544, 2007.
7) Kawaida H, Kono K, Takahashi A, et al: Distribution of CD4(+) CD25high regulatory T-cells in tumordraining lymph nodes in patients with gastric cancer. J Surg Res 124: 151-157, 2005.
10) Chen ML, Pittet MJ, Gorelik L, et al: Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc Natl Acad Sci USA 102: 419-424, 2005.
12) Strauss L, Bergmann C, Gooding W, et al: The frequency and suppressor function of CD4+CD25high Foxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13: 6301-6311, 2007.
13) Strauss L, Bergmann C, Szczepanski M, et al: A unique subset of CD4+CD25high Foxp3+ T cells secreting interleukin-10 and transforming growth factor β1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13: 4345-4354, 2007.
15) Strauss L, Bergmann C, Szczepanski MJ, et al: Expression of ICOS on human melanoma-infiltrating CD4+ CD25high Foxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol 180: 2967-2980, 2008.
20) van der Burg SH, Piersma SJ, de Jong A, et al: Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigen. Proc Natl Acad Sci US 4104:12087-12092, 2007.
22) Nair RE, Kilinc MO, Jones SA, et al: Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neutransgenic mice bearing advanced spontaneous tumors. J Immunol 176: 7325-7334, 2006.
26) Han Y, Guo Q, Zhang M, et al: CD69+CD4+CD25- T cell, a new subset of regulatory T cell, suppress T cells proliferation through membrane-bound TGF-β1. J Immunol 182: 111-120, 2009.
27) Alvaro T, Lejeune M, Salvado MT, et al: Outcome in Hodgikin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 11: 1467-1473, 2005.
29) Tzankov A, Meier C, Hirschmann P, et al: Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgikin's lymphoma. Haematologica 93: 193-200, 2008.
30) Zhao DM, Thornton AM, DiPaolo RJ, et al: Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 107: 3925-3932, 2006.
32) Salama P, Phillips M, Grieu F, et al: Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27: 186-192, 2009.
36) Marshall NA, Christie LE, Munro LR, et al: Immunosuppressive regulatory T cells are abundant in the eactive lymphocytes of Hodgikin lymphoma. Blood 103: 1755-1762, 2004.
37) Levings MK, Gregori S, Tresoldi E, et al: Differentiation of Trl cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 105: 1162-1169, 2005.
38) Fiore F, Nuschak B, Peola NB, et al: Exposure to myeloma cells lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells. Eur J Immunol 35: 1155-1163, 2005.
40) Bergmann C, Strauss L, Zeidler R, et al: Expansion of human T regulatory type l cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 67: 8865-8873, 2007.
41) Bergmann C, Strauss L, Wang Y, et al: Tregulatory type l cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 14: 3706-3715, 2008.
47) Xia ZW, Zhong WW, Meyrowitz JS, et al: The role of heme oxygenase-1 in T cell-mediated immunity: the all encompassing enzyme. Curr Pharm Des 14: 454-464, 2008.
50) Peng G, Wang HY, Peng W, et al: Tumor-infiltrating yδ T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 27: 334-348, 2007.
P.54 掲載の参考文献
6) Pak AS, Wright MA, Matthews JP, et al: Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34 (+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 1: 95-103, 1995.
7) Almand B, Resser J, Lindman B, et al: Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6: 1755-1766, 2000.
34) Terabe M, Matsui S, Park JM, et al: Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198: 1741-1752, 2003
35) Li H, Han Y, Guo Q, et al: Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β1. J Immunol 182: 240-249, 2009.
42) Rodriguez PC, Zea AH, DeSalvo J, et al: L-arginine consumption by macrophages modulates the expression of CD3ζ chain in T lymphocytes. J Immunol 171: 1232-1239, 2003.
50) Yanagisawa K, Exley MA, Jiang X, et al: Hyporesponsiveness to natural killer T-cell ligand α-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitoric oxide. Cancer Res 66: 11441-11446, 2006.
77) Kusmartsev S, Cheng F, Yu B, et al: All-trans-retinoic acid eliminates immature myeloid cells from tumorbearing mice and improves the effect of vaccination. Cancer Res 63: 4441-4449, 2003.
80) Pak AS, Ip G, Wright MA, et al: Treating tumor-bearing mice with low-dose γ-interferon plus tumor necrosis factor α to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy. Cancer Res 55: 885-890, 1995.
96) Van Ginderachter JA, Meerschaut S, Liu Y, et al: Peroxisome proliferator-activated receptor γ (PPARγ) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood 108: 525-535, 2006.
P.60 掲載の参考文献
1) Mosmann TR, Cherwinski H, Bond MW, et al: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348-2357, 1986.
28) Cortesini R: Pancreas cancer and the role of soluble immunoglobulin-like transcript 3 (ILT3).JOP 8: 697-703, 2007.
P.63 掲載の参考文献
P.64 掲載の参考文献
5) Hartmann E, Wollenberg B, Rothenfusser S, et al: Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 63: 6478-6487, 2003.
P.66 掲載の参考文献

C. 手術と免疫

P.70 掲載の参考文献
7) Lissoni P, Brivio F, Fumagalli L, et al: Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients. Anticancer Res 29: 1847-1852, 2009.
P.75 掲載の参考文献
9) Suzuki E, Kim S, Cheung H-K, et al: A novel small-molecule inhibitor of transforming growth factorβ type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 67: 2351-2359, 2007.
12) Fatouros M, Roukos DH, Lorenz M, et al: Impact of spleen preservation in patients with gastric cancer. Anticancer Res 25: 3023-3030, 2005.

D. 免疫療法

P.79 掲載の参考文献
P.87 掲載の参考文献
2) Shimizu J, Yamazaki S, Sakaguhi S: Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163: 5211-5218, 1999.
P.99 掲載の参考文献
10) Monteiro J, Batliwalla F, Ostrer H, et al: Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. J Immunol 156: 3587-3590, 1996.
39) Hu HM, Poehlein CH, Urba WJ, et al: Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 62: 3914-3919, 2002.
66) Sebestyen Z, Schooten E, Sals T, et al: Human TCR that incorporate CD3ζ induce highly preferred pairing between TCRα and β chains following gene transfer. J Immunol 180: 7736-7746, 2008.
P.104 掲載の参考文献
1) Hayday A, Tigelaar R: Immunoregulation in the tissues by γδ T cells. Nat Rev Immunol 3: 233-242, 2003.
2) Hayday AC: γδ T cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 18: 975-1026, 2000.
3) Martin B, Hirota K, Cua DJ, et al: Interleukin-17-producing γδ T cells selectively expand in response to pathogen products and environmental signals. Immunity 31: 321-330, 2009.
4) Roark CL, Simonian PL, Fontenot AP, et al: γδ T cells: an important source of IL-17. Curr Opin Immunol 20: 353-357, 2008.
5) Kabelitz D, Wesch D, He W: Perspectives of γδ T cells in tumor immunology. Cancer Res 67: 5-8, 2007.
6) Liu Z, Eltoum IE, Guo B, et al: Protective immunosurveillace and therapeutic antitumor activity of γδ T cells demonstrated in a mouse model of prostate cancer. J Immunol 180: 6044-6053, 2008.
7) Viey E, Fromont G, Escudier B, et al: Phosphostim-activated γδ T cells kill autologous metastatic renal cell Carcinoma. J Immunol 174: 1338-1347, 2005.
8) Wrobel P, Shojaei H, Schittek B, et al: Lysis of a broad range of epithelial tumour cells by human γδ T cells: involvement of NKG2D ligands and T-cell receptor-versus NKG2D-dependent recognition. Scand J Immunol 66: 320-328, 2007,
9) Bouet-Toussaint F, Cabillic F, Toutirais O, et al: Vγ9 Vδ2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol Immunother 57: 531-539, 2008.
10) Girardi M, Oppenheim DE, Steele CR, et al: Regulation of cutaneous malignancy by γδ T cells. Science 294: 605-609, 2001.
11) Gurardi M, Glusac E, Filler RB, et al: The distinct contributions of murine T cell receptor (TCR) γδ+ and TCRαβ+ T cells to different stages of chemically induced skin cancer. J Exp Med 198: 747-755, 2003.
13) Murayama M, Tanaka Y, Yagi J, et al: Antitumor activity and some immunological properties of γδ T-cells from patients with gastrointestinal carcinomas. Anticancer Res 28: 2921-2931, 2008.
14) Kondo M, Sakuta K, Noguchi A, et al: Zoledronate faciliates large-scale ex vivo expansion of functional γδ T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 10: 842-856, 2008.
15) Dieli F, Vermijlen D, Fulfaro F, et al: Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67: 7450-7457, 2007.
16) Takahara M, Miyai M, Tomiyama M, et al: Copulsing tumor antigen-pulsed dendritic cells with zoledronateefficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vγ9γδ T cell activation. J Leukoc Biol 83: 742-754, 2008.
20) Gong G, Shao L, Wang Y, et al: Phosphoantigen-activated Vγ2 Vδ2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection, Blood 113: 837-845, 2009.
P.107 掲載の参考文献
2) Takahashi T, Chiba S, Nieda M, et al: Cutting edge: analysis of human Vα24+CD8+ NKT cells activated by α-galactosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 168: 3140-3144, 2002.
7) Terabe M, Matsui S, Park JM, et al: Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198: 1741-1752, 2003.
9) Fichtner-Feigl S, Terabe M, Kitani A, et al: Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-α2. Cancer Res 68: 3467-3475, 2008.
10) Kawakami K, Terabe M, Kawakami M, et al: Characterization of a novel human tumor antigen interleukin-13 receptor α2 chain. Cancer Res 66: 4434-4442, 2006.
13) van der Vliet HJ, von Blomberg BM, Nishi N, et al: Circulating Vα24+Vβ11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 100: 144-148, 2001.
14) Molling JW, Kolgen W, van der Vliet HJ, et al: Peripheral blood IFN-γ-secreting Vα24+Vβ11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer 116: 87-93, 2005.
17) Tachibana T, Onodera H, Tsuruyama T, et al: Increased intratumor Vα24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res 11: 7322-7327, 2005.
18) Tahir SM, Cheng O, Shaulov A, et al: Loss of IFN-γ production by invariant NKT cells in advanced cance. J Immunol 167: 4046-4050, 2001.
19) van der Vliet HJ, Molling JW, Nishi N, et al: Polarization of Vα24+Vβ11+ natural killer T cells of healthy volunteers and cancer patients using α-galactosylceramide-loaded and enviromentally instructed dendritic cells. Cancer Res 63: 4101-4106, 2003.
22) Fujii S, Shimizu K, Kronenberg M, et al: Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide-loaded DCs. Nat Immunol 3: 867-874, 2002.
24) Yue SC, Shaulov A, Wang R, et al: CD1 ligation on human monocyte directly signals rapid NF-κB activation and production of bioactive IL-12. Proc Natl Acad Sci USA 102: 11811-11816, 2005.
26) Moreno M, Molling JW, von Mensdorff-Pouilly S, et al: IFN-γ-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses. J Immunol 181: 2446-2454, 2008.
27) Toura I, Kawano T, Akutsu Y, et al: Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J Immunol 163: 2387-2391, 1999.
28) Motohashi S, Kobayashi S, Ito T, et al: Preserved IFN-α production of circulating Vα24 NKT cells in primary lung cancer patients. Int J Cancer 102: 159-165, 2002.
29) Chang DH, Osman K, Connolly J, et al: Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201: 1503-1517, 2005.
30) Motohashi S, Nagato K Kunii N, et al: A phase I-II study of α-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 182: 2492-2501, 2009.
32) Kim YJ, Ko HJ, Kim YS, et al: α-Galactosylceramide-loaded, antigen-expressing B cells prime a wide spectrum of antitumor immunity. Int J Cancer 122: 2774-2783, 2008.
P.114 掲載の参考文献
1) Mosmann TR Cherwinski H, Bond MW, et al: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348-2357, 1986.
7) 臼井 崇: CD4+ヘルパーT細胞分化の基礎と臨床. 日臨免疫会誌 30: 419-427, 2007.
14) Mangan PR, Harrington LE, O'Quinn DB, et al: Transforming growth factor-β induces development of the TH17 lineage. Nature 441: 231-234, 2006.
15) Ivanov II, Mckenzie BS, Zhou L, et al: The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126: 1121-1133, 2006.
16) Zhou L, Lopes JE, Chong MM, et al: TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function. Nature 453: 236-240, 2008.
19) Xu L, Kitani A, Fuss I, et al: Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self induced to become Th17 cells in the absence of exogenous TGF-β. J Immunol 178: 6725-6729, 2007.
24) Ichiyama K, Yoshida H, Wakabayashi Y, et al: Foxp3 inhibits RORγt-mediated IL-17 A mRNA transcription through direct interaction with RORγt. J Biol Chem 283: 17003-17008, 2008.
26) Tanaka K, Ichiyama K, Hashimoto M, et al: Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-γon STAT3 and Smads. J Immunol 180: 3746-3756, 2008.
37) Tartour E, Fossiez F, Joyeux I, et al: Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 59: 3698-3704, 1999.

E. Immunogenic chemotherapy

P.123 掲載の参考文献
1) 折田薫三, 合地 明, 中村修治・他: 腫瘍の免疫逃避機構. Biotherapy 18: 279-294, 2004.
5) Nowak AK, Robinson BWS, Lake RA: Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63: 4490-4496, 2003.
29) Machiels JPH, Reilly RT, Emens LA, et al: Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cellvaccines in HER-2/neu tolerized mice. Cancer Res 61: 3689-3697, 2001.
30) Hermans IF, Chong TW, Palmowski MJ, et al: Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model, Cancer Res 63: 8408-8413, 2003.
45) Tong Y, Song W, Crystal RG: Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res 61: 7530-7535, 2001.
50) Berd D, Maguire HC Jr, Mastrangelo MJ: Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46: 2572-2577, 1986.
56) Yu B, Kusmartsev S, Cheng F, et al: Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage exprimental breast cancer Clin Cancer Res 9: 285-294, 2003.
57) Demaria S, Volm MD, Shapiro RL, et al: Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 7: 3025-3030, 2001.

F. 腫瘍免疫関連事項

P.144 掲載の参考文献
1) 折田薫三: 癌ワクチン療法におけるCD4+ T細胞の重要性. Biotherapy 21: 19-32, 2007.
25) Armstrong TD, Clements VK, Ostrand-Rosenberg S: MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. J Immunol 160: 661-666, 1998.
35) Gao FG, Kammanivong V, Liu WJ, et al: Antigen-specific CD4+ T cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res 62: 6438-6441, 2002.
38) Loyer V, Fontaine P, Pion S, et al: The in vivo fate of APCs displaying minor H antigen and/or MHC differences is regulated by CTLs specific for immunodominant class I-associated epitopes. J Immunol 163: 6462-6467, 1999.
46) Curtsinger JM, Schmidt CS, Mondino A, et al: Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol 162: 3256-3262, 1999.
54) Hochrein H, Shortman K, Vremec D, et al: Differential production of IL-12, IFN-α, and IFN-γ by mouse dendritic cell subsets. J Immunol 166: 5448-5455, 2001.
95) Sharfe N, Dadi HK, Shahar M, et al: Human immune disorder arising from mutation of the α-chin of the interleukin-2 receptor. Proc Natl Acad Sci USA 94: 3168-3171, 1997.
110) Luft T, Pang KC, Thomas E, et al: Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 161: 1947-1953, 1998.
114) Sikora AG, Jaffarzad N, Hailemichael Y, et al: IFN-α enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antituomor activity. J Immunol 182: 7398-7407, 2009.
115) Di Pucchio T, Pilla L, Capone I, et al: Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-α results in the activation of specific CD8+ T cells and monocyte/dendritic cell precursors. Caner Res 66: 4943-4951, 2006.
118) Bottomley A, Coens C, Suciu S, et al: Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 27: 2916-2923, 2009.
120) Ramos HJ, Davis AM, Cole AG, et al: Reciprocal responsiveness to interleukin-12 and interferon-α specifies human CD8+effector versus central memory T-cell fates. Blood 113: 5516-5525, 2009.
126) Schluns KS, Klonowski KD, Lefrancois L: Transregulation of memory CD8 T-cell proliferation by IL-15Rα+bone marrow-derived cells. Blood 103: 988-994, 2004.
135) Mortier E, Woo T, Advincula R, et al: IL-15Rα chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med 205: 1213-1225, 2008.
137) Stoklasek TA, Schluns KS, Lefrancois L: Combined IL-15/1L-15Rα immunotherapy maximizes IL-15 activity in vivo. J Immunol 177: 6072-6080, 2006.
138) Rubinstein MP, Kovar M, Purton JF, et al: Converting IL-15 to superagonist by binding to soluble IL-15Rα. Proc Natl Acad Sci USA 103: 9166-9171, 2006.
139) Epardaud M, Elpek KG, Rubinstein MP, et al: Interleukin-15/interleukin-15Rα complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res 68: 2972-2983, 2008.
142) Bachmann MF, Wolint P, Schwarz K, et al: Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor α and CD62L. J Immunol 175: 4686-4696, 2005.
150) Thedrez A, Harly C, Morice A, et al: IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human Vγ9 Vδ2 T cells for adoptive immunotherapy. J Immunol 182: 3423-3431, 2009.
163) Wang L, Miyahara Y, Kato T, et al: Essential roles of tumor-derived helper T cell epitopes for an effective peptide-based tumor vaccine. Cancer Immun 3: 16-28, 2003.
176) Phan V, Disis ML: Tumor-specific Th1 lymphocytes: modulation of the tumor microenvironment to enhance cross-priming. Am ASSOC Cancer Res (AACR) Educ Book 2009: 199-202, 2009.
P.155 掲載の参考文献
16) Espinosa E, Tabiasco J, Hudrisier D, et al: Synaptic transfer by humanγδ T cells stimulated with soluble or cellular antigens. J Immunol 168: 6336-6343, 2002.
17) Pardigon N, Takeda K, Saunier B, et al: CD8αα-mediated intraepithelial lymphocyte snatching of thymic leukemia MHC class I b molecules in vitro and in vivo. J Immunol 177: 1590-1598, 2006.
18) Fischer K, Voelkl S, Heymann J, et al: Isolation and characterization of human antigen-specific TCRαβ+CD4-CD8- double-negative regulatory T cells. Blood 105: 2828-2835, 2005.
P.169 掲載の参考文献
2) 折田薫三, 合地 明, 中村修治・他: Danger signal, Toll-like receptor と癌免疫療法. Biotherapy 16: 204- 210, 2002.
14) Xu D, Liu H, Komai-Koma M: Direct and indirect role of Toll-like receptors in T cell mediated immunity. Cell Mol immunol 1: 239-246, 2004.
18) Cho HJ, Hayashi T, Datta SK, et al: IFN-αβpromote priming of antigen-specific CD8+ and CD4+ T lymphocytes by immunostimulatory DNA-based vaccines. J Immunol 168: 4907-4913, 2002.
21) Zietara N, Lyszkiewicz M, Gekara N, et al: Absence of IFN-βimpairs antigen presentation capacity of splenic dendritic cells via down-regulation of heat shock protein 70. J Immunol 183: 1099-1109, 2009.
29) Shackleton M, Davis ID, Hopkins W, et al: The impact of imiquimod, a Toll-like receptor-7ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun 4: 9, 2004.
34) Ngoi SM, Tovey MG, Vella AT: Targeting poly (I:C) to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN-α/β. J Immunol 181: 7670-7680, 2008.
44) Curri AJ, van der Most RG, Broomfield SA, et al: Targeting the effector site with IFN-αβ-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J Immunol 180: 1535-1544, 2008.
45) Dumond FJ, Coker LZ: Interferon α/β enhances the expression of Ly-6 antigens on T cells in vivo and in vitro. Eur J Immunol 16: 735-740, 1986.
52) 小林元壮: OK-432 腫瘍内注入による胃癌所属リンパ節リンパ球の抗腫瘍能の増強. 日外会誌 91: 68-75, 1990.
55) Okamoto M, Oshikawa T, Tano T, et al: Involvement of toll-like receptor 4 signaling in interferon-γproduction and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst 95: 316-326, 2003.
58) Saito K, Yajima T, Nishimura H, et al: Soluble branchedβ-(1,4) glucans from Acetobacter species show strong activities to induce interleukin-12 in vitro and inhibit T-helper 2 cellular response with immunoglobulin E production in vivo. J Biol Chem 278: 38571-38578, 2003.

G. 免疫抑制T細胞

P.172 掲載の参考文献
P.187 掲載の参考文献
2) Zhao DM, Thornton AM, DiPaolo RJ, et al: Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 107: 3925-3932, 2006.
3) Ghiringhelli F, Menard C, Terme M, et al: CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J Exp Med 202: 1075-1085, 2005.
6) 新田 剛, 高浜洋介: 中枢性トレランスと自己免疫疾患. Jpn J Clin Immunol 29: 8-15, 2006.
16) Malek TR, Yu A, Vincek V, et al: CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice. Immunity 17: 167-178, 2002.
41) Kinjyi I, Inoue H, Hamano S, et al: Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factorβ1. J Exp Med 203:1021-1031, 2006.
53) Li J, Hu P, Khawli LA, et al: Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25+ T-cell depletion. Cancer Res 63:8384-8392, 2003.
54) Zheng SG, Wang JH, Stohl W, et al: TGF-βrequires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+regulatory cells. J immunol 176:3321-3329, 2006.
56) Li R, Perez N, Karumuthil-Melethil S, et al: Enhanced engagement of CTLA-4 induces antigen-specific CD4+CD25+Foxp3+and CD4+CD25-TGF-β1+adaptive regulatory T cells. J Immmunol 179:5191-5203, 2007.
63) So T, Croft M: Cutting edge: OX40 inhibits TGF-β-and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells. J Immunol 179:1427-1430, 2007.
65) Sharma R, Zheng L, Deshmukh US, et al: Cutting edge: a regulatory T cell-dependent novel function of CD25 (IL-2Rα) controlling memory CD8+ T cell homeostasis. J Immunol 178:1251-1255, 2007.
68) Lehmann J, Huehn J, de la Rosa M, et al: Expression of the integrin αEβ7 identifies unique subsets of CD25+as well as CD25-regulatory T cells. Proc Natl Acad Sci USA 99:13031-13036, 2002.
72) Siewert C, Lauer U, Cording S, et al: Experience-driven development: Effetor/memory-like αE+ Foxp3 regulatory T cells originate from both naive T cells and naturally occurring naive-like regulatory T cells. J Immunol 80:146-155, 2008.
80) Marie JC, Letterio JJ, Gavin M, et al: TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+regulatory T cells. J Exp Med 201:1061-1067, 2005.
81) Zheng SG, Wang JH, Gray JD, et al: Natural and induced CD4+CD25+ cells educate CD4+CD25 cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10. J Immunol 172:5213-5221, 2004.
82) Selvaraj RK, Geiger TL: A kinetic and dynamic analysis of FoxP3 induced in T cells by TGF-β. J Immunol 178:7667-7677, 2007.
84) Pyzik M, Piccirillo CA: TGF-β1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets. J Leukoc Biol 82:335-346, 2007.
85) Gorelik L, Fields PE, Flavell RA: Cutting edge: TGF-βinhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol 165:4773-4777, 2000.
86) Mantel PY, Kuipers H, Boyman O, et al: GATA3-driven Th2 responses inhibit TGF-β1-induced FOXP3 expression and the formation of regulatory T cells. PloS Biol 5:e329, 2007.
88) Skapenko A, Kalden JR, Lipsky PE, et al: The IL-4 receptorα-chain-binding cytokines, IL-4 and IL-13,induce forkhead box P3-expressing CD25+CD4+regulatory T cells from CD25-CD4+precursors. J Immunol 175:6107-6116, 2005.
90) Taylor AW, Namba K: In vitro induction of CD25+CD4+regulatory T cells by the neuropeptide alpha-melanocyte stimulating hormone (α-MSH). Immunol Cell Biol 79:358-367, 2001.
91) Namba K, Kitaichi N, Nishida T, et al: Induction of regulatory T cells by the immunomodulating cytokines α-melanocyte-stimulating hormone and transforming growth factor-β2. J Leukoc Biol 72:946-952, 2002.
92) Luger TA, Brzoska T:α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis 66(Suppl 3):iii52-iii55, 2007.
99) DiPaolo RJ, Brinster C, Davidson TS, et al: Autoantigen-specific TGFβ-induced Foxp3+ regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells. J Immunol 179:4685-4693, 2007.
109) Feunou P, Vanwetswinkel S, Gaudray F, et al: Foxp3+CD25+ T regulatory cells stimulate IFN-γ-independent CD152-mediated activation of tryptophan catabolism that provides dendritic cells with immune regulatory activity in mice unresponsive to staphylococcal enterotoxin B.J Immunol 179:910-917, 2007.
115) Giroux M, Yurchenko E, St-Pierre J, et al: Tregulatory cells control numbers of NK cells and CD8α+ immature dendritic cells in the lymph node paracortex. J Immunol 179:4492-4502, 2007.
129) Strauss L, Bergmann C, Szczepanski M, et al: A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-β1 mediates suppression in tumor microenvironment. Clin Cancer Res l3:4345-4354, 2007.
132) Oida T, Zhang X, Goto M, et al: CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-β-dependent mechanism.J Immunol 170:2516-2522,2003.
133) Nakamura K, Kitani A, Fuss I, et al:TGF-βl plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and nice.J Immunol l72:834-842, 2004.
134) Oida T, Xu L, Weiner HL, et al: TGF-β-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling.J Immunol 177:2331-2339, 2006.
135) Fahlen L Read S, Gorelik L, et al: T cells that cannot respond to TGF-βescape control by CD4+CD25+ regulatory T cells.J Exp Med 201:737-746, 2005.
136) Li MO, Wan YY, Flavell RA: T cell-produced transforming growth factor-β1 controls T cell tolerance andregulates Th1-and Th17-cell differentiation. Immunity 26:579-591, 2007.
140) Chen ML, Yan BS, Bando Y, et al: Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFβ-mediated function and enhanced suppression of experimental autoimmune encephalornyelitis. J Immunol 180:7327-7337, 2008.
143) Oberle N, Eberhardt N, Falk CS, et al: Rapid suppression of cytokine transcription in human CD4+CD25- T cells by CD4+Foxp3+ regulatory T cells: independence of IL-2 consumption, TGF-β, and various inhibitors of TCR signaling. J Immunol 179:3578-3587, 2007.

b. Adaptive CD8+Treg細胞

P.206 掲載の参考文献
17) Belghith M, Bluestone JA, Barriot S, et al: TGF-β-dependent mechanisms mediate restoration of self tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9: 1202-1208, 2003.
19) Ciubotariu R, Colovai AI, Pennesi G, et al: Specific suppression of human CD4+ Th cell responses to pig MHC antigens by CD8+CD28- regulatory T cells. J Immunol 161: 5193-5202, 1998.
25) Ciubotariu R, Li J, Colovai AI, et al: Human xenospecific T suppressor cells inhibit T helper cell proliferation to porcine aortic endothelial cells, and NF-κB activity in porcine APC. Hum Immunol 62: 470-478, 2001.
28) Hahn BH, Singh RP, La Cava A, et al: Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFβ-secreting CD8+ T cell suppressors. J Immunol 175: 7728-7737, 2005.
36) Guillonneau C, Hill M, Hubert FX, et al: CD401g treatment results in allograft acceptance mediated by CD8+CD45Rclow T cells, IFN-γ, and indoleamine 2, 3-dioxygenase. J Clin Invest 117: 1096-1106, 2007.
47) Endharti AT, Rifa IM, Shi Z, et al: Cutting edge: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-γ production and proliferation of CD8+ T cells. J Immunol 175: 7093-7097, 2005.
53) Balashov KE, Khoury SJ, Hafler DA, et al: Inhibition of T cell responses by activated human CD8+ T cellsis mediated by interferon-γ and is defective in chronic progressive multiple sclerosis. J Clin Invest 95: 2711-2719, 1995.
59) Myers L, Croft M, Kwon BS, et al: Peptide-specific CD8 T regulatory cells use IFN-γ to elaborate TGF-β-based suppression. J Immunol 174: 7625-7632, 2005.
65) Garba ML, Pilcher CD, Bingham AL, et al: HIV antigens can induce TGF-β1-producng ImmunoregulatoryCD8+ T cells. J Immunol 168: 2247-2254, 2002.
66) Alatrakchi N, Graham CS, van der Vliet HJJ, et al: Hepatitis C virus(HCV)-specific CD8+ cells producetransforming growth factor β that can suppress HCV-specific T-cell responses. J Virol 81: 5882-5892, 2007.
70) Furlan R, Bergami A, Cantarella D, et al: Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-γ. Eur J Immunol 33: 1830-1838, 2003.
73) Tutaj M, Szczepanik M: Mechanisms involved in the regulation of Immune response in experimental autoimmune encephalomyelitis in mice. Postepy Hig Med Dosw 60: 571-583, 2006.
76) Tang X, Maricic I, Purohit N, et al: Regulation of Immunity by a novel population of Qa-1-restricted CD8αα+TCRαβ+ T cells. J Immunol 177: 7645-7655, 2006.
86) Jonuleit H, Schmitt E, Kakirman H, et al: Infectious tolerance: human CD25+ regulatory T cells convey suppressor activity to conventionl CD4+ T helper cells. J Exp Med 196: 255-260, 2002.
87) Selvaraj RK, Geiger TL: Mitigation of experimental allergic encephalomyelitis by TGF-β induced Foxp3+ regulatory T lymphocytes through the induction of anergy and infectious tolerance. J Immunol 180: 2830-2838, 2008.
93) Antica M, Scollay R: Development of lymphocytes at extrathymic sites. J Immunol 163: 206-211, 1999.
95) 中村修司: 新しいタイプのヒト制御性T細胞 (HOZOT) の発見と臨床応用. Jpn J Clin Immunol 32: 223- 230, 2009.
104) Chen W, Ford MS, Young KJ, et al: The role and mechanisms of double negative regulatory T cells in the suppression of immune responses. Cell Mol Immunol 1: 328-335, 2004.
105) Fischer K, Voelkl S, Heymann J, et al: Isolation and characterization of human antigen-specific TCR αβ+CD4-CD8-double-negative regulatory T cells. Blood 1O5: 2828-2835, 2005.
P.227 掲載の参考文献
7) Palucka AK, Ueno H, Fay J, et al: Role of dendritic cells in cancer immunootherapy. PPO Focus, Cancer Innunol 1 (1), 2007.
45) Gandhi R, Anderson DE, Weiner HL: Cutting edge: immature human dendritic cells express latencyassociated peptide and inhibit T cell activation in a TGF-β-dependent manner. J Immunol 178: 4017-4021, 2007.
64) Stagg AJ, Kamm MA, Knight SC: Intestinal dendritic cells increase T cell expression of α4β7 integrin. Eur J Immunol 32: 1445-1454, 2002.
72) Bilsborough J, George TC, Norment A, et al: Mucosal CD8α+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology 108: 481-492, 2003.
79) Chung Y, Chang JH, Kweon MN, et al: CD8α-CD11b+ dendritic cells but not CD8α+ dendritic cells mediate cross-tolerance toward intestinal antigens. Blood 106: 201-206, 2005.
81) Tutaj M, Szczepanik M: Epicutaneous (EC) immunization with myelin basic protein (MBP) induces TCRαβ+ CD4+ CD8+ double positive suppressor cells that protect from experimental autoimmune encephalomyelitis (EAE). J Autoimmun 28: 208-215, 2007.
82) Szczepanik M, Bryniarski K, Tutaj M, et al: Epicutaneous immunization induces αβ T-cell receptor CD4 CD8 double-positive non-specific suppressor T cells that inhibit contact sensitivity via transforming growth factor-β. Immunology 115: 42-54, 2005.
83) Szczepanik M, Tutaj M, Bryniarski K, et al: Epicutaneously induced TGF-β-dependent tolerance inhibits experimental autoimmune encephalomyelitis. J Neuroimmunol 164: 105-114, 2005.
93) Ito M, Minamiya Y, Kawai H, et al: Tumor-derived TGFβ-1 induces dendritic cell apoptosis in the sentinel lymph node. J Immunol 176: 5637-5643, 2006.
94) Ishinaga H, Jono H, Lim JH, et al: TGF-β induces p65 acetylation to enhance bacteria-induced NF-κB activation. EMBO J 26: 1150-1162, 2007.
97) Kosiewicz MM, Alard P, Liang S, et al: Mechanisms of tolerance induced by transforming growth factor-β-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand. Int Immunol 16: 697-706, 2004.
103) Rutella S, Bonanno G, Pierelli L, et al: Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-α. Eur J Immunol 34: 1291-1302,2004.
109) Ank N, Iversen MB, Bartholdy C, et al: An important role for type III Interferon (IFN-λ/IL-28) in TLR-induced antiviral activity. J Immunol 180: 2474-2485, 2008.
110) Mennechet FJ, Uze G: Interferon-λ-treated dendritic cells specifically induce proliferation of Foxp3-expressing suppressor T cells. Blood 107: 4417-4423, 2006.
113) Fabricius D, O'Dorisio MS, Blackwell S, et al: Human plasmacytoid dendritic cell function: inhibition of IFN-α secretion and modulation of immune phenotype by vasoactive intestinal peptide. J Immunol 177: 5920-5927, 2006.
121) Iruretagoyena MI, Sepulveda SE, Lezana JP, et al: Inhibition of nuclear factor-κB enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther 318: 59-67, 2006.
139) Tan PH, Sagoo P, Chan C, et al: Inhibition of NF-κB and oxidative pathways in human dendritic cells by antioxidative vitamins generates regulatory T cells. J Immunol 174: 7633-7644, 2005.

最近チェックした商品履歴

Loading...